tcsc0267 Panobinostat

Order Now

AVAILABLE SIZES

$943.00 ORDERING INFORMATION International
TAICLONE BIOTECH CORP.
order@taiclone.com
+886-2-2735-9682
+886-2-2735-9807

Data sheet

Download PDF Datasheet

Technical Inquries

Submit Review

Product Description

Panobinostat is an oral histone deacetylase (HDAC) inhibitor with a multi-targeted profile.

In Vitro: Panobinosta (LBH589) induces apoptosis of both MOLT-4 and Reh cells in a time- and dose-dependent manner. Panobinosta treatment results in histone (H3K9 and H4K8) hyperacetylation and regulation of cell-cycle control genes in Reh cells[1]. Panobinostat exhibites potent antiproliferative activity in human NSCLC cell lines with the IC50 ranging from 5 to 100 nM[2].

In Vivo: Panobinosta (10, 20 mg/kg, i.p.) significantly slows tumor growth derived from Meso and NSCLC cells in vivo models. Panobinosta markedly increases acetylation of histone H3 and H4 of H69 human SCLC cells harvest from SCID mice[2]. Panobinostat (5, 10 and 20 mg/kg i.p.) demonstrates a clear benefit of decreased tumor burden, significantly improves TTE and reduces bone density loss in a disseminated multiple myeloma mouse model[3].

Information

CAS No404950-80-7
FormulaC21H23N3O2
Clinical Informationclinicalinformation
PathwayAutophagy
Epigenetics
Cell Cycle/DNA Damage
TargetAutophagy
HDAC
HDAC

Specifications

Purity / Grade>98%
SolubilityDMSO : ≥ 57 mg/mL (163.12 mM)
Smilessmiles

Misc Information

Alternative NamesLBH589;NVP-LBH589
Observed Molecular Weight349.43
Get valuable resources and offers directly to your email.